SPECS
TAILORx
The Trial Assigning Individualized Options for Treatment (TAILORx), a trial that grew out of a PACCT working group, tested whether a set of expressed genes that has been shown to be associated with risk of recurrence in women with node-negative, hormone receptor-positive breast cancer can be used to assign patients to the most appropriate and effective treatment. The signature tested was the 21-gene Oncotype DX® panel developed by Genomic Health, Inc. The trial was designed and led by ECOG-ACRIN and supported by a collaborative effort between the CDP and CTEP. Accrual was completed in 2010. Initial reports were published in 2015 with more reports published in 2018. Breast cancer stamp sales by the US Postal Service played a critical role in making a groundbreaking treatment trial possible by providing a portion of the funding for TAILORx. Without this support, the trial would not have been possible.
The TAILORx Breast Cancer Trial
An Innovative Approach to Research Funding
New England Journal of Medicine Nov 19, 2015
New England Journal of Medicine Jul 12, 2018
TAILORx SCHEMA
For more information, please visit http://www.cancer.gov/types/breast/research/tailorx